![]() We also show how breaking down organizational silos in an international biopharmaceutical company accelerates the development of precision medicines. We demonstrate how data literacy and interoperability can improve real-time inter- and intra-organizational collaboration while maintaining a high level of data quality and governance. This project highlights how a data-driven culture, supported by an innovative technological solution, increases data discoverability and quality, contributing to a substantial reduction in operational costs and gains in productivity and efficiency. Precision medicine is driven by large interoperable datasets, high-performance computing, and cross-functional collaboration. ![]() ![]() Learn more about this project during the team’s presentation in the AI for Oncology, Precision Medicine, and Health track, Thursday, May 5, 12:25-12:55pm By coupling deep phenotypic information with liquid biopsy results, more targeted drug development, better clinical trial optimization and more powerful post market research are all enabled. Using NLP, key information such as TNM stage, biomarker profile, tumor histology, smoking history and performance status is now extracted from the patient narrative and transformed to normalized, structured data with precision of up to 100% for certain variables (see table 1). Built on Guardant360 liquid biopsy results, Guardant INFORM combines large volumes of genomic and clinical data to help accelerate research and development of next generation cancer therapeutics. This is the driving force behind an initiative by Guardant Health to use state of the art text mining and Natural Language Processing (NLP) to structure and normalize complex clinical variables from clinical documents in the real-world clinical-genomic platform – Guardant INFORM. In the area of precision oncology, the more availability of high-quality clinical data that enables additional stratified insights to be gleaned, the better. ![]() Learn more about this project during the team’s presentation in the Software Applications and Services track on Wednesday May 4, 3:40-4:10pm In the twenty months since program inception, these technologies have been deployed against 70% of our small molecule projects and have significantly impacted several areas including molecular ideation, library design decisions, synthetic route planning, patent research and writing and have already contributed to accelerations in the discovery pipeline. The Augmented Drug Design platform uses centralized data access guided by FAIR data principles and high-performance computational modeling coupled with AI/ML insights to provide our scientists with novel drug design capabilities. Augmented Drug Design is the program driving AstraZeneca’s efforts in the Drug Design space with the aim of significantly reducing the time to develop candidate drugs. The Pharmaceutical industry is seeking to accelerate Drug Discovery through a renewed focus on the valuable data it has accumulated and find ways to use these data far more effectively through the use of Artificial Intelligence and Machine Learning techniques that were previously impossible. ![]() Here are the four winning projects, as described in their own words. “This year, our panel of peer judges were particularly impressed with efforts to shift processes and data culture to empower data science and AI, with comprehensive and integrated tools for drug discovery, and with forward-thinking approaches to structuring and normalizing both clinical and real-world data.Ģ022 Bio-IT World Innovative Practices Awards Winners “The Bio-IT World community consistently delivers innovation to drive the life sciences forward,” said Allison Proffitt, Bio-IT World Editorial Director. This year’s winners represent excellence in innovation in the categories of Clinical & Health-IT, IT Infrastructure, Knowledge Management, and Personalized & Translational Medicine. Since 2003, Bio-IT World has hosted an elite awards program with the goal of highlighting outstanding examples of how technology innovations and strategic initiatives can be applied to advance life sciences research. The awards ceremony will be held during the plenary program on Tuesday, May 3, at the 2022 Bio-IT World Conference & Expo in Boston. Four grand prize awards were granted to AstraZeneca, Guardant Health with IQVIA, Merck KGaA with Genedata, and Quantum Leap Healthcare Collaborative / University of California San Francisco with OpenClinica. Ap| Bio-IT World today announced the 2022 Innovative Practices Awards winners. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |